Aydan Köken Avşar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aydan Köken Avşar has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Fatos Onen
Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Türkiye
4 shared publications - Ismail Sari
Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Türkiye
4 shared publications - Merih Birlik
Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
4 shared publications - Servet Akar
Division of Rheumatology, Department of Internal Medicine, Izmir Katip Celebi University Faculty of Medicine, Izmir, Turkey
3 shared publications - Abdurrahman Soner Şenel
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkey
2 shared publications - Ayse Cefle
Division of Rheumatology, Department of Internal Medicine, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye
2 shared publications
Latest Publications
- Open Access
- 21 March 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (2) , 292-297
Does the presence of comorbidities in rheumatoid arthritis patients impact initial tumor necrosis factor inhibitor treatment response and retention rates?
Aims: We aimed to evaluate the effect of comorbidities on the first tumor necrosis factor inhibitor (TNFi) treatment response and retention in patients with rheumatoid arthritis (RA). Methods: The study included adult RA patients (with M05 and M06 ICD codes) registered in the TURKBIO database and receiving their first TNFi treatment. Data on demographic, clinical, and laboratory features, disease activity scores, and other follow-up parameters (at the beginning and months 6 and 12) were collected. The Log-Rank test and Kaplan-Meier curve were used to determine the TNFi retention rates. Results: There were 1172 bio-naive RA patients who initiated their first TNFi treatments. The median age (IQR) of the patients was 53 (51-61), and 79.8% (n=935) were women. The most commonly used TNFi was etanercept (38.9%), followed by adalimumab (27.9%), certolizumab (13.8%), golimumab (10.8%), and infliximab (8.7%). The most prevalent comorbidities in patients were hypertension (32.6%), obesity (32.6%), osteoporosis (22.3%), asthma/COPD (17.9%), and diabetes mellitus (15.7%). The presence of comorbidities at the beginning of TNFi treatment did not affect DAS28 CRP responses at months 6 and 12 (p=0.18 and p=0.83, respectively) and the continuation rates of the first TNFi drug. After conducting a thorough analysis that factored in variables including gender, age over 60 years, smoking, serologic status, presence of erosion, and basal disease activity scores, it was determined that there were no statistically significant hazard ratios (HR) for the first TNFi persistence. However, there was a 5% decrease in adherence to the first TNFi drug with an increase in median disease duration (HR 0.95, 95% CI=0.90-1.00, p=0.048). Conclusion: It has been observed that the presence of comorbidities in patients with RA does not significantly affect the TNFi treatment response and retention rate. However, evidence suggests that as the duration of the disease increases, the continuation of the first TNFi drug may decrease.
- 21 March 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (2) , 292-297
Open AccessDoes the presence of comorbidities in rheumatoid arthritis patients impact initial tumor necrosis factor inhibitor treatment response and retention rates?
Aims: We aimed to evaluate the effect of comorbidities on the first tumor necrosis factor inhibitor (TNFi) treatment response and retention in patients with rheumatoid arthritis (RA). Methods: The study included adult RA patients (with M05 and M06 ICD codes) registered in the TURKBIO database and receiving their first TNFi treatment. Data on demographic, clinical, and laboratory features, disease activity scores, and other follow-up parameters (at the beginning and months 6 and 12) were collected. The Log-Rank test and Kaplan-Meier curve were used to determine the TNFi retention rates. Results: There were 1172 bio-naive RA patients who initiated their first TNFi treatments. The median age (IQR) of the patients was 53 (51-61), and 79.8% (n=935) were women. The most commonly used TNFi was etanercept (38.9%), followed by adalimumab (27.9%), certolizumab (13.8%), golimumab (10.8%), and infliximab (8.7%). The most prevalent comorbidities in patients were hypertension (32.6%), obesity (32.6%), osteoporosis (22.3%), asthma/COPD (17.9%), and diabetes mellitus (15.7%). The presence of comorbidities at the beginning of TNFi treatment did not affect DAS28 CRP responses at months 6 and 12 (p=0.18 and p=0.83, respectively) and the continuation rates of the first TNFi drug. After conducting a thorough analysis that factored in variables including gender, age over 60 years, smoking, serologic status, presence of erosion, and basal disease activity scores, it was determined that there were no statistically significant hazard ratios (HR) for the first TNFi persistence. However, there was a 5% decrease in adherence to the first TNFi drug with an increase in median disease duration (HR 0.95, 95% CI=0.90-1.00, p=0.048). Conclusion: It has been observed that the presence of comorbidities in patients with RA does not significantly affect the TNFi treatment response and retention rate. However, evidence suggests that as the duration of the disease increases, the continuation of the first TNFi drug may decrease.
- Open Access
- 30 June 2024
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 39 (2) , 232-241
Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results
Objectives: This study aims to investigate the effect of age on disease activity and biological treatment in patients with ankylosing spondylitis (AS). Patients and methods: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined as
- 30 June 2024
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 39 (2) , 232-241
Open AccessBiological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results
Objectives: This study aims to investigate the effect of age on disease activity and biological treatment in patients with ankylosing spondylitis (AS). Patients and methods: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined as
- 15 March 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (10) , 2227-2237
Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that is associated with systemic inflammatory conditions. Currently, there is no universally accepted standard therapy for PG, but immunosuppressive (IS) treatment seems essential. We report a patient here who was successfully treated with tofacitinib despite being PG-refractory to multiple anti-tumor necrosis factor alpha (anti-TNF) therapies and conventional IS. In addition, we performed a comprehensive review of all cases of PG treated with JAK inhibitors. We identified 27 cases treated with JAK inhibitors. Approximately 80% of the patients achieved complete recovery within a median of 12 weeks, even though 17 patients (63%) had received biologics before JAKinib treatment. Notably, this recovery could appear as early as 2 weeks. JAK inhibitors may prove useful in the future, particularly for treating immunosuppressive and steroid-resistant pyoderma gangrenosum, according to recent case reports.
- 15 March 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (10) , 2227-2237
Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that is associated with systemic inflammatory conditions. Currently, there is no universally accepted standard therapy for PG, but immunosuppressive (IS) treatment seems essential. We report a patient here who was successfully treated with tofacitinib despite being PG-refractory to multiple anti-tumor necrosis factor alpha (anti-TNF) therapies and conventional IS. In addition, we performed a comprehensive review of all cases of PG treated with JAK inhibitors. We identified 27 cases treated with JAK inhibitors. Approximately 80% of the patients achieved complete recovery within a median of 12 weeks, even though 17 patients (63%) had received biologics before JAKinib treatment. Notably, this recovery could appear as early as 2 weeks. JAK inhibitors may prove useful in the future, particularly for treating immunosuppressive and steroid-resistant pyoderma gangrenosum, according to recent case reports.
- 10 August 2023
- Published by Springer Nature in Rheumatology International
- Vol. 44 (12) , 3009-3015
Quantitative analysis of JAK/STAT signaling pathway in patients of inflammatory skin disorders
Background Inflammatory skin diseases (ISDs), are characterized by dysregulated activation of innate and adaptive immune systems, with inflammatory cytokines playing a crucial role in their pathogenesis. Objectives This study aimed to investigate the involvement of Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway in the pathogenesis of ISDs. Methods The study analyzed a total of 117 skin biopsies, comprising 31 from pyoderma gangrenosum (PG), 25 from hidradenitis suppurativa (HS), 35 from psoriasis patients, and 26 from control subjects. To assess the expression levels of JAK/STAT pathway components, immunohistochemical staining was performed on both the dermal and epidermal layers of the skin. The Histo score (H score) was utilized as the immunoexpression score to evaluate the staining intensity. Results The results indicated that all components of the JAK/STAT signaling pathway, except JAK2 and STAT6 in PG, JAK1, STAT4, and STAT6 in HS, and JAK1 in psoriasis, were overexpressed in the dermal skin compared to the control group (p < 0.05). Psoriatic skin had higher expression of STAT6 than both PG and HS and higher expression of JAK2 than PG (p < 0.05). Additionally, HS biopsies had higher expression of JAK2 and STAT6 compared to PG (p < 0.05). JAK1 expression was higher in PG than in HS, psoriasis, and the control group (mean H score was 265.8, 184.8, 191.4, and 113.1, p < 0.05, respectively). Conclusions This study provides new insights into the potential contribution of the JAK/STAT pathway to the pathogenesis of ISDs. The findings suggest that targeting this pathway could be a promising therapeutic strategy for treating these disorders.
- 10 August 2023
- Published by Springer Nature in Rheumatology International
- Vol. 44 (12) , 3009-3015
Quantitative analysis of JAK/STAT signaling pathway in patients of inflammatory skin disorders
Background Inflammatory skin diseases (ISDs), are characterized by dysregulated activation of innate and adaptive immune systems, with inflammatory cytokines playing a crucial role in their pathogenesis. Objectives This study aimed to investigate the involvement of Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway in the pathogenesis of ISDs. Methods The study analyzed a total of 117 skin biopsies, comprising 31 from pyoderma gangrenosum (PG), 25 from hidradenitis suppurativa (HS), 35 from psoriasis patients, and 26 from control subjects. To assess the expression levels of JAK/STAT pathway components, immunohistochemical staining was performed on both the dermal and epidermal layers of the skin. The Histo score (H score) was utilized as the immunoexpression score to evaluate the staining intensity. Results The results indicated that all components of the JAK/STAT signaling pathway, except JAK2 and STAT6 in PG, JAK1, STAT4, and STAT6 in HS, and JAK1 in psoriasis, were overexpressed in the dermal skin compared to the control group (p < 0.05). Psoriatic skin had higher expression of STAT6 than both PG and HS and higher expression of JAK2 than PG (p < 0.05). Additionally, HS biopsies had higher expression of JAK2 and STAT6 compared to PG (p < 0.05). JAK1 expression was higher in PG than in HS, psoriasis, and the control group (mean H score was 265.8, 184.8, 191.4, and 113.1, p < 0.05, respectively). Conclusions This study provides new insights into the potential contribution of the JAK/STAT pathway to the pathogenesis of ISDs. The findings suggest that targeting this pathway could be a promising therapeutic strategy for treating these disorders.
- Open Access
- 12 May 2023
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 10 (2) , 50-56
The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients
Objective: Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect, systemic immunosuppression is not expected, and this may have a negative effect on the extra-intestinal symptoms of inflammatory bowel disease, particularly spondyloarthritis. Currently, there is limited data regarding the effect of vedolizumab on spondyloarthritis symptoms. We aimed to investigate whether vedolizumab has an effect on the occurrence of rheumatological symptoms and the clinical course of patients who have spondyloarthritis. Methods: Thirty-nine adult inflammatory bowel disease patients who were followed up in the Gastroenterology Clinic and treated with vedolizumab were included in the study. Patients were reviewed in terms of rheumatological manifestations. The occurrence of new musculoskeletal findings during the vedolizumab treatment was recorded. Patients with a former diagnosis of spondyloarthritis were evaluated for the activity of axial and peripheral manifestations during the vedolizumab. Results: There were 39 inflammatory bowel disease patients (29 Crohn’s disease, 10 ulcerative colitis, 48.7% (n = 19) male) who had been treated with vedolizumab. The mean age of the patients was 41.4 ± 15.7 years, and the duration of inflammatory bowel disease was 10.4 ± 7.5 years. A total of 17 (44%) patients had accompanying spondyloarthritis findings (mean age 47.08 ± 15.325 years and 58.8% M). Seven patients had axial dominant symptoms and 6 of them were in an active disease state before vedolizumab. During vedolizumab, all but 1 continued to be active. There were 14 patients with arthritis/arthralgias before vedolizumab and only 3 had improvement with therapy. On the other hand, there were 3 patients who had new-onset arthralgias/arthritis with vedolizumab. In total, 6 patients needed to stop vedolizumab because of spondyloarthritis activation (n = 2) and uncontrolled inflammatory bowel disease (n = 4), respectively. Conclusion: Treatment with vedolizumab seems no effect on both the occurrence and the course of rheumatological manifestations in inflammatory bowel disease patients. Further studies are required to replicate our results. Cite this article as: Huseynzada S, Yüce Inel T, Hajiyev F, et al. The effect of vedolizumab on spondyloarthritis symptoms in a cohort of inflammatory bowel disease patients. Eur J Rheumatol 2023;10(2):50-56.
- 12 May 2023
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 10 (2) , 50-56
Open AccessThe Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients
Objective: Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect, systemic immunosuppression is not expected, and this may have a negative effect on the extra-intestinal symptoms of inflammatory bowel disease, particularly spondyloarthritis. Currently, there is limited data regarding the effect of vedolizumab on spondyloarthritis symptoms. We aimed to investigate whether vedolizumab has an effect on the occurrence of rheumatological symptoms and the clinical course of patients who have spondyloarthritis. Methods: Thirty-nine adult inflammatory bowel disease patients who were followed up in the Gastroenterology Clinic and treated with vedolizumab were included in the study. Patients were reviewed in terms of rheumatological manifestations. The occurrence of new musculoskeletal findings during the vedolizumab treatment was recorded. Patients with a former diagnosis of spondyloarthritis were evaluated for the activity of axial and peripheral manifestations during the vedolizumab. Results: There were 39 inflammatory bowel disease patients (29 Crohn’s disease, 10 ulcerative colitis, 48.7% (n = 19) male) who had been treated with vedolizumab. The mean age of the patients was 41.4 ± 15.7 years, and the duration of inflammatory bowel disease was 10.4 ± 7.5 years. A total of 17 (44%) patients had accompanying spondyloarthritis findings (mean age 47.08 ± 15.325 years and 58.8% M). Seven patients had axial dominant symptoms and 6 of them were in an active disease state before vedolizumab. During vedolizumab, all but 1 continued to be active. There were 14 patients with arthritis/arthralgias before vedolizumab and only 3 had improvement with therapy. On the other hand, there were 3 patients who had new-onset arthralgias/arthritis with vedolizumab. In total, 6 patients needed to stop vedolizumab because of spondyloarthritis activation (n = 2) and uncontrolled inflammatory bowel disease (n = 4), respectively. Conclusion: Treatment with vedolizumab seems no effect on both the occurrence and the course of rheumatological manifestations in inflammatory bowel disease patients. Further studies are required to replicate our results. Cite this article as: Huseynzada S, Yüce Inel T, Hajiyev F, et al. The effect of vedolizumab on spondyloarthritis symptoms in a cohort of inflammatory bowel disease patients. Eur J Rheumatol 2023;10(2):50-56.
- 14 March 2022
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 10 (1) , 43-47
Training Course Results of the Assessment of Modified Rodnan Skin Score in Scleroderma
- 14 March 2022
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 10 (1) , 43-47
Training Course Results of the Assessment of Modified Rodnan Skin Score in Scleroderma
- Open Access
- 31 December 2021
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 36 (4) , 510-517
A preliminary study of possible fibrotic role of meprin metalloproteases in scleroderma patients
Objectives: This study aims to investigate the possible fibrotic role of meprin metalloproteases and possible fibrotic effects of activator protein-1 (AP-1) in scleroderma patients. Patients and methods: Between April 2018 and April 2019, a total of 85 scleroderma patients (9 males, 76 females; mean age: 54.9 years; range, 22 to 80 years) who met the 2013 American College of Rheumatology/European League Against Rheumatism criteria and 80 healthy control individuals (10 males, 70 females; mean age 42.9 years; range, 19 to 65 years) were included. Patients’ data and blood samples were collected. Messenger ribonucleic acid expressions of interleukin (IL)-6, AP-1 subunits, and tumor necrosis factor-alpha (TNF-α) were analyzed by quantitative real-time polymerase chain reaction. Serum meprin alpha and beta protein levels were analyzed using the enzyme-linked immunosorbent assay. Results: Meprin alpha and meprin beta protein levels increased in scleroderma patients. The AP-1 subunits (c-Fos, c-Jun), IL-6, and TNF-α increased in scleroderma patients, compared to controls. Conclusion: Our results provide evidence showing that increased meprins levels may be related to AP-1 levels and increased meprins levels may responsible for increased inflammatory TNF-α and IL-6 levels. All these data suggest meprins as promising therapeutic targets to restore the balance between inflammation and extracellular matrix deposition in scleroderma.
- 31 December 2021
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 36 (4) , 510-517
Open AccessA preliminary study of possible fibrotic role of meprin metalloproteases in scleroderma patients
Objectives: This study aims to investigate the possible fibrotic role of meprin metalloproteases and possible fibrotic effects of activator protein-1 (AP-1) in scleroderma patients. Patients and methods: Between April 2018 and April 2019, a total of 85 scleroderma patients (9 males, 76 females; mean age: 54.9 years; range, 22 to 80 years) who met the 2013 American College of Rheumatology/European League Against Rheumatism criteria and 80 healthy control individuals (10 males, 70 females; mean age 42.9 years; range, 19 to 65 years) were included. Patients’ data and blood samples were collected. Messenger ribonucleic acid expressions of interleukin (IL)-6, AP-1 subunits, and tumor necrosis factor-alpha (TNF-α) were analyzed by quantitative real-time polymerase chain reaction. Serum meprin alpha and beta protein levels were analyzed using the enzyme-linked immunosorbent assay. Results: Meprin alpha and meprin beta protein levels increased in scleroderma patients. The AP-1 subunits (c-Fos, c-Jun), IL-6, and TNF-α increased in scleroderma patients, compared to controls. Conclusion: Our results provide evidence showing that increased meprins levels may be related to AP-1 levels and increased meprins levels may responsible for increased inflammatory TNF-α and IL-6 levels. All these data suggest meprins as promising therapeutic targets to restore the balance between inflammation and extracellular matrix deposition in scleroderma.